The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis
Thieme. All rights reserved..
Nonalcoholic steatohepatitis (NASH) and alcoholic hepatitis (ASH) are advanced forms of fatty liver diseases that are associated with a high morbidity and mortality worldwide. Patients with ASH or NASH are more susceptible to the progression of fibrosis and cirrhosis up to the development of hepatocellular carcinoma. Currently, there are limited medical therapies available. Accompanied by the asymptomatic disease progression, the demand for liver transplants is high. This review provides an overview about the growing evidence for a central role of NLR family pyrin domain containing 3 (NLRP3) inflammasome, a multiprotein complex that acts as a central driver of inflammation via activation of caspase 1, maturation and release of pro-inflammatory cytokines including interleukin-1β, and trigger of inflammatory pyroptotic cell death in both NASH and ASH. We also discuss potential therapeutic approaches targeting NLRP3 inflammasome and related upstream and downstream pathways to develop prognostic biomarkers and medical treatments for both liver diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Seminars in liver disease - 40(2020), 3 vom: 07. Aug., Seite 298-306 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Knorr, Jana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Inflammasomes |
|---|
| Anmerkungen: |
Date Completed 14.09.2021 Date Revised 14.09.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1055/s-0040-1708540 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311060129 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311060129 | ||
| 003 | DE-627 | ||
| 005 | 20231225141437.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1055/s-0040-1708540 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1036.xml |
| 035 | |a (DE-627)NLM311060129 | ||
| 035 | |a (NLM)32526788 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Knorr, Jana |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.09.2021 | ||
| 500 | |a Date Revised 14.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Thieme. All rights reserved. | ||
| 520 | |a Nonalcoholic steatohepatitis (NASH) and alcoholic hepatitis (ASH) are advanced forms of fatty liver diseases that are associated with a high morbidity and mortality worldwide. Patients with ASH or NASH are more susceptible to the progression of fibrosis and cirrhosis up to the development of hepatocellular carcinoma. Currently, there are limited medical therapies available. Accompanied by the asymptomatic disease progression, the demand for liver transplants is high. This review provides an overview about the growing evidence for a central role of NLR family pyrin domain containing 3 (NLRP3) inflammasome, a multiprotein complex that acts as a central driver of inflammation via activation of caspase 1, maturation and release of pro-inflammatory cytokines including interleukin-1β, and trigger of inflammatory pyroptotic cell death in both NASH and ASH. We also discuss potential therapeutic approaches targeting NLRP3 inflammasome and related upstream and downstream pathways to develop prognostic biomarkers and medical treatments for both liver diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Inflammasomes |2 NLM | |
| 650 | 7 | |a NLR Family, Pyrin Domain-Containing 3 Protein |2 NLM | |
| 700 | 1 | |a Wree, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Tacke, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Feldstein, Ariel E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Seminars in liver disease |d 1993 |g 40(2020), 3 vom: 07. Aug., Seite 298-306 |w (DE-627)NLM012599093 |x 1098-8971 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2020 |g number:3 |g day:07 |g month:08 |g pages:298-306 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1055/s-0040-1708540 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2020 |e 3 |b 07 |c 08 |h 298-306 | ||